Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Maj K. Kjeldsen; Morten Jørgensen; Dina Sofie B. Grønseth; Martin Schønemann-Lund; Gitte Bettina Nyvang; Charlotte Aaquist Haslund; Anja Oer Knudsen; Anne Krejbjerg Motavaf; Susanne Malander; Maarit Anttila; Gabriel Lindahl; Johanna Mäenpää; Maria Dimoula; Theresa L. Werner; Trine Zeeberg Iversen; Sakari Hietanen; Lars Fokdal; Hanna Dahlstrand; Line Bjørge; Michael J. Birrer; Mansoor R. Mirza; Maria Rossing

doi:10.1158/2767-9764.CRC-24-0294

Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Maj K. Kjeldsen, Morten Jørgensen, Dina Sofie B. Grønseth, Martin Schønemann-Lund, Gitte Bettina Nyvang, Charlotte Aaquist Haslund, Anja Oer Knudsen, Anne Krejbjerg Motavaf, Susanne Malander, Maarit Anttila, Gabriel Lindahl, Johanna Mäenpää, Maria Dimoula, Theresa L. Werner, Trine Zeeberg Iversen, Sakari Hietanen, Lars Fokdal, Hanna Dahlstrand, Line Bjørge, Michael J. BirrerMansoor R. Mirza, Maria Rossing

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

Original language	English
Journal	Cancer research communications
Volume	4
Issue number	12
Pages (from-to)	3190-3200
Number of pages	11
ISSN	2767-9764
DOIs	https://doi.org/10.1158/2767-9764.CRC-24-0294
Publication status	Published - 2024

Bibliographical note

Publisher Copyright:
©2024 The Authors; Published by the American Association for Cancer Research.

Access to Document

10.1158/2767-9764.CRC-24-0294Licence: CC BY

FulltextFinal published version, 2.16 MBLicence: CC BY

Cite this

Kjeldsen, M. K., Jørgensen, M., Grønseth, D. S. B., Schønemann-Lund, M., Nyvang, G. B., Haslund, C. A., Knudsen, A. O., Motavaf, A. K., Malander, S., Anttila, M., Lindahl, G., Mäenpää, J., Dimoula, M., Werner, T. L., Iversen, T. Z., Hietanen, S., Fokdal, L., Dahlstrand, H., Bjørge, L., ... Rossing, M. (2024). Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer. Cancer research communications, 4(12), 3190-3200. https://doi.org/10.1158/2767-9764.CRC-24-0294

Kjeldsen, MK, Jørgensen, M, Grønseth, DSB, Schønemann-Lund, M, Nyvang, GB, Haslund, CA, Knudsen, AO, Motavaf, AK, Malander, S, Anttila, M, Lindahl, G, Mäenpää, J, Dimoula, M, Werner, TL, Iversen, TZ, Hietanen, S, Fokdal, L, Dahlstrand, H, Bjørge, L, Birrer, MJ, Mirza, MR & Rossing, M 2024, 'Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer', Cancer research communications, vol. 4, no. 12, pp. 3190-3200. https://doi.org/10.1158/2767-9764.CRC-24-0294

@article{f7a8d4c85e0d43cfacbe85c14b1085f6,

title = "Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer",

abstract = "SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.",

author = "Kjeldsen, {Maj K.} and Morten J{\o}rgensen and Gr{\o}nseth, {Dina Sofie B.} and Martin Sch{\o}nemann-Lund and Nyvang, {Gitte Bettina} and Haslund, {Charlotte Aaquist} and Knudsen, {Anja Oer} and Motavaf, {Anne Krejbjerg} and Susanne Malander and Maarit Anttila and Gabriel Lindahl and Johanna M{\"a}enp{\"a}{\"a} and Maria Dimoula and Werner, {Theresa L.} and Iversen, {Trine Zeeberg} and Sakari Hietanen and Lars Fokdal and Hanna Dahlstrand and Line Bj{\o}rge and Birrer, {Michael J.} and Mirza, {Mansoor R.} and Maria Rossing",

note = "Publisher Copyright: {\textcopyright}2024 The Authors; Published by the American Association for Cancer Research.",

year = "2024",

doi = "10.1158/2767-9764.CRC-24-0294",

language = "English",

volume = "4",

pages = "3190--3200",

journal = "Cancer research communications",

issn = "2767-9764",

publisher = "American Association for Cancer Research",

number = "12",

}

TY - JOUR

T1 - Beyond HRD Status

T2 - Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

AU - Kjeldsen, Maj K.

AU - Jørgensen, Morten

AU - Grønseth, Dina Sofie B.

AU - Schønemann-Lund, Martin

AU - Nyvang, Gitte Bettina

AU - Haslund, Charlotte Aaquist

AU - Knudsen, Anja Oer

AU - Motavaf, Anne Krejbjerg

AU - Malander, Susanne

AU - Anttila, Maarit

AU - Lindahl, Gabriel

AU - Mäenpää, Johanna

AU - Dimoula, Maria

AU - Werner, Theresa L.

AU - Iversen, Trine Zeeberg

AU - Hietanen, Sakari

AU - Fokdal, Lars

AU - Dahlstrand, Hanna

AU - Bjørge, Line

AU - Birrer, Michael J.

AU - Mirza, Mansoor R.

AU - Rossing, Maria

PY - 2024

Y1 - 2024

N2 - SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

AB - SIGNIFICANCE: The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

U2 - 10.1158/2767-9764.CRC-24-0294

DO - 10.1158/2767-9764.CRC-24-0294

M3 - Journal article

C2 - 39591206

AN - SCOPUS:85214054632

SN - 2767-9764

VL - 4

SP - 3190

EP - 3200

JO - Cancer research communications

JF - Cancer research communications

IS - 12

ER -